Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multi-platform genomic analysis of matched well- and dedifferentiated liposarcomas identify novel risk and progression determinants [aCGH]

ABSTRACT: To define mechanisms that regulate biological behavior in well- and dedifferentiated liposarcoma (WD/DDLS) subsets, we describe an integrative analysis of DNA sequence, copy number and gene expression in 9 paired WDLS and DDLS samples with validation cohorts and in vitro studies. Amplification of 12q13-15 was common to all WDLS; 6q23-25 amplifications were observed 18% of WDLS and were associated with increased TAB2 and higher local recurrence risk versus non-6q-amplified WDLS. TAB2 knockdown decreased MDM2 protein expression and induced markers of cellular senescence in 6q23-25-amplified WDLS cells but not in non-amplified WDLS of amplified DDLS cells. Amplification of 6q23-25 was not associated with DDLS recurrence risk or progression from WDLS to DDLS. Instead, pathogenic ATRX mutations, recurrent losses in 13q and gains in 8q12-21 accompanied dedifferentiation. Downregulation of the 13q-encoded genes MYCBP2 and IRS2 was observed in DDLS versus WDLS; in vitro, these genes were essential for WDLS cell differentiation. Taken together, this study defines a copy number-driven model of liposarcoma initiation, progression, and differentiation. Array comparative genomic hybridization (aCGH) was performed using Agilent 244K or 1M arrays and analyzed using the RAE pipeline as previously reported (Barretina J, et. al, Nat Genet. 2010;42(8):715-21, PMC2911503 and Crago AM, et. al, Clin Cancer Res. 2012;18(5):1334-40, PMC3294014)

ORGANISM(S): Homo sapiens

PROVIDER: GSE336156 | GEO | 2026/08/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Multi-platform genomic analysis of matched well- and dedifferentiated liposarcomas identify novel risk and progression determinants

Project description:To define mechanisms that regulate biological behavior in well- and dedifferentiated liposarcoma (WD/DDLS) subsets, we describe an integrative analysis of DNA sequence, copy number and gene expression in 9 paired WDLS and DDLS samples with validation cohorts and in vitro studies. Amplification of 12q13-15 was common to all WDLS; 6q23-25 amplifications were observed 18% of WDLS and were associated with increased TAB2 and higher local recurrence risk versus non-6q-amplified WDLS. TAB2 knockdown decreased MDM2 protein expression and induced markers of cellular senescence in 6q23-25-amplified WDLS cells but not in non-amplified WDLS of amplified DDLS cells. Amplification of 6q23-25 was not associated with DDLS recurrence risk or progression from WDLS to DDLS. Instead, pathogenic ATRX mutations, recurrent losses in 13q and gains in 8q12-21 accompanied dedifferentiation. Downregulation of the 13q-encoded genes MYCBP2 and IRS2 was observed in DDLS versus WDLS; in vitro, these genes were essential for WDLS cell differentiation. Taken together, this study defines a copy number-driven model of liposarcoma initiation, progression, and differentiation.

2026-08-04 | GSE244163 | GEO

Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma (DDLS) part 2

2013-09-24 | GSE50750 | GEO

Targeting eIF4A-dependent translation in soft tissue sarcoma

Project description:Well-differentiated and dedifferentiated liposarcoma (WD/DDLS), myxofibrosarcoma (MFS), and undifferentiated pleomorphic sarcoma (UPS) are the most common types of genetically complex sarcoma. There is an urgent need to develop effective targeted therapy for the over 50% of patients who eventually die of disease. Despite their genetic complexity, all four sarcoma types rely on the oncogenic translation of Hippo pathway proteins, which requires the RNA helicase eIF4A (DDX2). Pharmacological inhibition of eIF4A using CR-1-31B effectively suppressed tumor growth and induced apoptosis in DDLS, MFS, and UPS patient-derived cell lines and mouse xenografts. Transcriptome-scale ribosome footprinting identified eIF4A-dependent mRNAs in DDLS, MFS, and UPS cell lines. These include Hippo pathway effectors such as YAP1, WWTR1 (TAZ), and TEAD1. Combined knockdown of YAP and TAZ induced apoptosis in DDLS, MFS, and UPS cell lines, implicating them as critical targets. Hence, DDLS, MFS, and UPS rely on the eIF4A-dependent and CR-1-31B-sensitive translation of Hippo pathway oncogenes such as YAP, TAZ, and TEAD. eIF4A thus represents a new, promising therapeutic target for these incurable forms of soft tissue sarcoma.

2025-12-14 | GSE227676 | GEO

12q amplification in liposarcoma

Project description:12q amplification in liposarcoma

| PRJEB64351 | ENA

Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma (DDLS) part 2

Project description:Analysis of DNA copy number variations in two DDLS tumor-derived cell lines DDLS8817 and LPS141 growing in culture in basal conditions The goal of this DNA copy number analysis was to determine if genes used in signaling network modeling in DDLS were amplified or deleted Genomic DNA was isolated from asynchronously growing DDLS8817 and LPS141 cultures growing in basal conditions using the Qiagen DNAy kit.

2013-09-24 | E-GEOD-50750 | biostudies-arrayexpress

Project description:Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma (DDLS)

| PRJNA218739 | ENA

Expression changes following siRNA knockdown of ADRM1 in ovarian cell line OAW42

Project description:Knock-down of ovarian cancer amplification target ADRM1 leads to down regulation of GIPC1 and up-regulation of RECK. Among 20q13-amplified genes in ovarian cancer, ADRM1 overexpression was the most highly correlated with amplification, and was significantly upregulated with respect to stage, recurrence and metastasis. In addition, overexpression of ADRM1 correlated significantly with shorter time to recurrence and overall survival. Herein, array-CGH and microarray expression of ovarian cancer cell lines, provides evidence consistent with the primary tumor data that ADRM1 is a 20q13 amplification target. Knock-down of ADRM1 in amplified ovarian cell line OAW42 results in down-regulation of growth factor GIPC1 and up-regulation of tumor-suppressor RECK RNA and protein. In our dataset of 141 ovarian primary tumors, ADRM1 overexpression significantly correlates with GIPC1 overexpression. In addition, there is a significant anticorrelation between ADRM1 overexpression and RECK expression. Further research is necessary to determine whether targeting knock-down of ADRM1 in 20q13-amplified ovarian cancers results in growth inhibition and tumor suppression via downstream targets GIPC1 and RECK.

2011-01-14 | GSE26634 | GEO

EGFR pathway expression persists in recurrent glioblastoma independent of amplification status

Project description:Background: Glioblastoma mortality is driven by tumour progression or recurrence despite administering a therapeutic arsenal consisting of surgical resection, radiation, and alkylating chemotherapy. The genetic changes underlying tumour progression and chemotherapy resistance are poorly understood. Methods: In this work, we sought to define the relationship between EGFR amplification status, EGFR mRNA expression, and EGFR pathway activity. We compared RNA-sequencing data from matched primary and recurrent tumour samples (N = 40 patients, 20 with EGFR amplification). Results: In the setting of glioblastoma recurrence, the EGFR pathway was overexpressed regardless of EGFR amplification status, suggesting a common genomic endpoint in recurrent glioblastoma, although EGFR amplification did associate with higher EGFR mRNA expression. Three of forty patients in the study cohort had EGFR-amplified tumours and received targeted EGFR therapy. Their molecular subtypes and clinical outcomes did not significantly differ from patients who received conventional chemotherapy. Conclusion: Our findings suggest that while the EGFR amplification may confer a unique molecular profile in primary glioblastoma, pathway analysis reveals upregulation of the EGFR pathway in recurrence, regardless of amplification status. As such, the EGFR pathway may be a key mediator of glioblastoma progression.

2023-01-25 | GSE222515 | GEO

Homo sapiens

Project description:Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma (DDLS) part 1

| PRJNA218742 | ENA

Homo sapiens

Project description:Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma (DDLS) part 2

| PRJNA218741 | ENA